A committee of outside advisers to the U.S. Food and Drug Administration (FDA) recommended a vaccine from GlaxoSmithKline (GSK) against the respiratory syncytial virus (RSV) for adults over age 60. The vote from the Vaccines and Related Biological Products Advisory Committee (VRBPAC) for GSK’s Arexvy (RSVPreF3-AS01) vaccine comes a day after the 12 members voted to endorse Pfizer’s vaccine candidate, Abrysvo…
Biden Administration Stops Shipments of COVID-19 Treatment to All States
April 6, 2022
admin
AMERICABrightCCP VirusCovid NewsEditor's PicksExecutive BranchGlaxoSmithKlinehealthHealth NewsPoliticssotrovimabUS
0 Comment
The U.S. government on March 5 immediately halted all shipments of a COVID-19 treatment to states and ordered health care providers not to use the drug. The actions were taken because of the increasing prevalence of BA.2, a subvariant of Omicron, which is itself a variant of the CCP (Chinese Communist Party) virus, also known as SARS-CoV-2,…
GSK to Get $1.25 Billion to Settle HIV Drug Patent Row With Gilead
Britain’s GlaxoSmithKline will receive $1.25 billion from Gilead Sciences as part of a settlement between its HIV medicines unit and the U.S.-based drugmaker, ending a long-drawn patent dispute. The settlement, announced by GSK on Tuesday, relates to Gilead’s antiretroviral drug Biktarvy, a medicine used to check the AIDS-causing virus, which GSK said in 2018 infringed…
Treat COVID-19 Like ‘Common Cold,’ Says British Trust, While Pledging $22 Billion for Vaccine Research
January 13, 2022
admin
AstraZeneca VaccineCCP Viruscharitable foundationsExpert ViewGlaxoSmithKlineUKvaccine researchVaccines & SafetyWorld
0 Comment
Pandemic-related lockdowns of economies are no longer practical, according to Britain’s largest charitable foundation focused on health research, which has called for moving toward treating COVID-19 “like the common cold.” “I don’t think it can mean going back into regular lockdowns, because it is just not economically viable. We don’t do that for the flu,…
Glaxo Says Its COVID-19 Antibody Treatment Effective Against Omicron
December 7, 2021
admin
antibody treatmentBusiness & EconomyCCP VirusCompaniesCoronavirus In-DepthGlaxoSmithKlineHealth NewsMind & BodyOmicronPUBLIC HEALTH INFORMATIONTreatments and TechniquesVaccines & Safety
0 Comment
British drugmaker GlaxoSmithKline said early-stage lab data shows its COVID-19 monoclonal antibody treatment, jointly developed with U.S. partner Vir Biotechnology, is effective against all mutations of the new Omicron strain. Glaxo said in a Dec. 7 statement that new preclinical findings generated from in vitro testing of the drug, called sotrovimab, show that the treatment…
Florida Acquires Monoclonal Antibodies From GlaxoSmithKline After Biden Administration’s Rationing
The state of Florida has obtained thousands of monoclonal antibody treatments from a British company after the Biden administration’s abrupt rationing of federally acquired doses. Florida went to GlaxoSmithKline, which produces monoclonals that have not yet been bought up by the federal government. It reached an agreement on 3,000 doses, Gov. Ron DeSantis announced Thursday….
EU Signs Deal With GSK for Supply of Potential COVID-19 Drug
BRUSSELS—The European Union has signed a contract with GlaxoSmithKline (GSK) for the supply of up to 220,000 treatments of its investigational monoclonal antibody therapy sotrovimab against COVID-19, it said on Wednesday. The drug, which is developed together with U.S. firm Vir Biotechnology, can be used for the treatment of high-risk coronavirus patients with mild symptoms…
US News
RSS Error: A feed could not be found at `https://www.theepochtimes.com/c-us/feed`; the status code is `200` and content-type is `text/html; charset=utf-8`